Value through Innovation27 July 2016

Clinical Study Results

  • BILR 355 - Healthy
    Clinical Study Number 1188.1
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    A double-blind (at each dose level), randomised, placebo-controlled single increasing dose safety, tolerability and preliminary pharmacokinetics study in healthy male volunteers after oral administration of BILR 355 BS solved in PEG 400 (dosage: 1 - 200 mg)

    Study Document Trial synopsis 1188.1 english
  • BILR 355 - Healthy
    Clinical Study Number 1188.10
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    Pharmacokinetic Interaction Study of BILR 355 BS Plus Ritonavir with Truvada

    Study Document Trial synopsis 1188.10_CO english
  • BILR 355 - HIV Infections
    Clinical Study Number 1188.2
    Study Indication HIV Infections
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    Randomized Placebo Controlled Dose Escalation Study of Safety, Tolerability Pharmacokinetics and Efficacy of BILR 355 BS in Healthy Volunteers and HIV-Infected Subjects

    Study Document Trial synopsis 1188.2_CO english
  • BILR 355 - Healthy
    Clinical Study Number 1188.32
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    Open Label, Single Dose Escalation Trial of BILR 355 (SDS) Plus Ritonavir in Healthy Volunteers

    Study Document Trial synopsis 1188.32_CO english
  • BILR 355 - Healthy
    Clinical Study Number 1188.33
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    Open Label Relative Bioavilability Study of Tablet and Capsules of SDS Formulations in Healthy Volunteers

    Study Document Trial synopsis 1188.33_CO english
  • BILR 355 - Healthy
    Clinical Study Number 1188.4
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    An open study to investigate the effect of two times oral 100 mg ritonavir capsules on pharmacokinetics of single doses of BILR 355 BS (dose steps: 5 and 12.5 mg) solved in 5 ml PEG 400 after oral administration in healthy male volunteers

    Study Document Trial synopsis 1188.4 english
  • BILR 355 - Healthy
    Clinical Study Number 1188.5
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    Single Dose Relative Bioavailability of BILR 355 BS newTablet and suspension formulations compared to current 1b formulation

    Study Document Trial synopsis 1188.5_CO english
  • BILR 355 - Healthy
    Clinical Study Number 1188.6
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    An open study to investigate the effect of different boosting agents on pharmacokinetics of single doses of BILR 355 BS (dose steps: 5 and 12.5 mg) dissolved in 5 mL PEG 400 after oral administration in healthy male volunteers

    Study Document Trial synopsis 1188.6 english
  • BILR 355 - Healthy
    Clinical Study Number 1188.7
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    Pharmacokinietic interaction trial between tipranivir plus ritonavir and BILR 355 BS

    Study Document Trial synopsis 1188.7_CO english
  • BILR 355 - Healthy
    Clinical Study Number 1188.8
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    Trial of Pharmacokinetic Interaction between Lopinivir plus ritonavir and BILR 355 BS

    Study Document Trial synopsis 1188.8_CO english
  • BILR 355 - Healthy
    Clinical Study Number 1188.9
    Study Indication Healthy
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase I
    Study Title

    Study of Pharmacokinetic Interaction between Combivir (ZDV+3TC) and BILR 355 BS plus ritaonavir

    Study Document Trial synopsis 1188.9_CO english
  • BILR 355 - HIV Infections
    Clinical Study Number 1188.31
    Study Indication HIV Infections
    Product BILR 355
    Generic Name BILR 355
    Lab Code
    Clinical Phase IIa
    Study Title

    Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTVboosted BILR 355 (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day combination therapy with Tipranavir or Lopinavir based HAART-regimen

    Study Document Trial statement 1188.31 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.